Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05375097 · ClinicalTrials.gov registry record
Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.
A clinical trial of Migraine, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 162
- Enrollment target
- 1
- Study location
NCT05375097 is a study of Migraine that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 162 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05375097, a study of Migraine, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 162 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a retrospective registry-based study utilizing data collected in association with clinical care of patients. All data was stored in electronic health records at Terveystalo data base, and no patients were contacted for the study.
Conditions Studied
Interventions
- OTHER Erenumab
Study Locations (1)
New Jersey
- Novartis Investigative Site - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2020-07-03 |
| Est. Completion | 2021-05-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05375097
The ClinicalTrials.gov registry entry for NCT05375097 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (55% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Erenumab is the first listed.
NCT05375097 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05375097 about?
NCT05375097 is a clinical study titled "Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.". This was a retrospective registry-based study utilizing data collected in association with clinical care of patients. All data was stored in electronic health records at Terveystalo data base, and no patients were contacted for the study.
What is the current status of trial NCT05375097?
This trial is currently completed. The enrollment target is 162 participants. The study started on 2020-07-03. Estimated completion is 2021-05-14.
What conditions does trial NCT05375097 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT05375097?
The interventions under investigation include: Erenumab (OTHER).
Who is sponsoring clinical trial NCT05375097?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05375097 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.